Fund moves
5.0%Stake
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ACB · NASDAQ · Medicinal Chemicals & Botanical Products · Foreign private issuer
Aurora Cannabis (ACB) · oqro.io/stocks/ACB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$4.94−0.05 (−1.00%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Aurora Cannabis is on record in SEC filings since 2006.
No open-market sale by an insider of Aurora Cannabis (ACB) was filed with the SEC in the last 90 days.
No trade in Aurora Cannabis (ACB) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+12.5% (+$0.55) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $4.39 on Nov 13, 2025 to $4.94 on Nov 13, 2026 (+12.5%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Medicinal Chemicals & Botanical Products company based in Edmonton, Alberta, Canada. Foreign private issuer: reports on Form 20-F or 40-F.
Medicinal Chemicals & Botanical Products company based in Edmonton, Alberta, Canada. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
+12.5%
Market value
–
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 8.42M shares sold short, +2.7% vs the previous count, 12.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
2 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 12, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
2 tracked managers disclosed the same change for Q1 2025. Among this manager's largest new positions for Q1 2025.
Congress
Traded Feb 12, 2021 · disclosed 7 days later
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Against the S&P 500 over the year
Since Nov 11, 2025, ACB is up 8.6% and the index fund is up 10.4%: 2 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ACB moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.